Allist(SH:688578) Zheng Quan Zhi Xing·2025-08-08 16:23Core Viewpoint - The shareholders of Shanghai Ailis Pharmaceutical Technology Co., Ltd. plan to reduce their holdings by a total of up to 13,500,000 shares, which represents no more than 3.00% of the company's total share capital, through block trades and centralized bidding transactions starting from September 1, 2025 [1][13]. Shareholder Holding Situation - As of the announcement date, the employee stockholding platforms, Shanghai Aixiang Enterprise Development Center (Limited Partnership) and Nantong Aiyun Enterprise Development Center (Limited Partnership), hold 32,930,660 shares (7.32%) and 9,770,362 shares (2.17%) respectively, both acquired before the company's initial public offering [1][2]. Reduction Plan Details - The reduction plan will take place over a period of three months starting from September 1, 2025, with a maximum of 13,500,000 shares to be sold, which is less than 1.00% of the total share capital. The plan includes a maximum of 9,000,000 shares to be sold through block trades, accounting for up to 2.00% of the total share capital [1][2][13]. Impact on Company Control - The implementation of this reduction plan will not lead to any change in the company's control or governance structure, nor will it significantly impact the company's ongoing operations [2][13]. Compliance with Regulations - The reduction plan complies with relevant laws and regulations, including the Securities Law of the People's Republic of China and the Shanghai Stock Exchange's guidelines for shareholder reductions. The shareholders have committed to adhere to these regulations during the reduction process [14].